(Q37515346)

20 August 2017

1 reference

title

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors (English)

1 reference

20 August 2017

Mark J Bishton

2

0 references

Ricky W Johnstone

object named as

Ricky W Johnstone

series ordinal

3

0 references

author name string

H Miles Prince

series ordinal

1

1 reference

PubMed ID

19519200

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

5

1 reference

20 August 2017

601-612

1 reference

The epigenomics of cancer

20 August 2017

1 reference

21 January 2018

Epigenetics in cancer

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Chromatin modifications and their function

21 January 2018

1 reference

Histone deacetylases and cancer

21 January 2018

1 reference

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

21 January 2018

1 reference

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

21 January 2018

1 reference

Recent advances in Hsp90 inhibitors as antitumor agents

21 January 2018

1 reference

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.36

1 reference

20 August 2017

1 reference

PubMed ID

19519200